Coburg ON-based
FSD Pharma Inc. (
CSE: HUGE ,
OTC: HUGE,
Forum) – a life sciences holding company dedicated to building a portfolio of assets and biotech solutions – has announced that Crystal Research Associates LLC has released an Executive Informational Overview (EIO) on FSD Pharma. The 58-page paid report can be found on FSD Pharma's
website.
Or, click
here for full news release.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. – a wholly owned subsidiary – is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (PEA) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (Lucid) – a wholly owned subsidiary – is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: FSD Pharma Inc. is a client of Stockhouse Publishing.